Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes
Open Access
- 1 January 2022
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 243, 177-186
Abstract
No abstract availableKeywords
Funding Information
- Johnson and Johnson
- Pfizer
- Sanofi
- Astellas Pharma US
- Baxter International
- Janssen Pharmaceutica
- Swedish Research Council
- AstraZeneca
- LEO Pharma Research Foundation
This publication has 33 references indexed in Scilit:
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.American Journal of Epidemiology, 2016
- The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativenessClinical Kidney Journal, 2015
- Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney DiseaseJAMA, 2015
- Sodium Zirconium Cyclosilicate in HyperkalemiaNew England Journal of Medicine, 2015
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS InhibitorsNew England Journal of Medicine, 2015
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- HFSA 2010 Comprehensive Heart Failure Practice GuidelineJournal of Cardiac Failure, 2010
- Clinical utility of trace proteinuria for microalbuminuria screening in the general populationClinical and Experimental Nephrology, 2007
- Comparison of Dynamic Treatment Regimes via Inverse Probability WeightingBasic & Clinical Pharmacology & Toxicology, 2006
- Validating recommendations for coronary angiography following acute myocardial infarction in the elderlyJournal of Clinical Epidemiology, 2001